Welcome to our dedicated page for Advansix SEC filings (Ticker: ASIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Navigating Advansix’s labyrinth of disclosures—spanning raw-material hedging, air-emission permits, and nylon capacity utilisation—can feel overwhelming. Environmental liabilities, commodity price swings, and multi-site production data often hide deep inside a 300-page 10-K. Investors seeking a clear picture of how caprolactam spreads affect margins or how regulatory changes hit plant nutrients need more than a PDF download.
This page assembles every filing�10-K annual reports, 10-Q quarterly earnings, 8-K material events, Section 16 Form 4 insider transactions, and proxy statements—in real time, straight from EDGAR. Want the Advansix insider trading Form 4 transactions? They’re timestamped and searchable. Looking for the latest Advansix quarterly earnings report 10-Q filing or an Advansix proxy statement executive compensation breakdown? One click reveals AI-generated summaries, key tables, and red-flag alerts, so you can focus on decisions, not decoding accounting notes.
Stock Titan’s AI reads every footnote, surfaces segment sales for nylon, chemical intermediates, and plant nutrients, and highlights forward-looking risk language. Receive email or Slack alerts for Advansix Form 4 insider transactions real-time, compare year-over-year cash-flow trends, or track plant outage disclosures via Advansix 8-K material events explained. Whether you’re assessing dividend safety, benchmarking fertilizer exposure, or spotting Advansix annual report 10-K simplified KPIs, our platform transforms dense filings into clear, actionable insight—no Excel gymnastics required. It’s Advansix SEC filings explained simply, backed by AI you can trust.
FedEx Corporation (FDX) � Form 144 filing
The filer has notified the SEC of an intent to sell up to 3,610 shares of FedEx common stock through Merrill Lynch (Dallas) on or about 9 July 2025. Based on the filing’s market reference, the stake is valued at roughly $861,743. FedEx reports 237,823,884 shares outstanding, so the proposed sale represents only about 0.0015 % of the float.
The shares were originally acquired on 28 September 2015 via a cash-paid stock-option exercise. The filer reports no other sales in the past three months and certifies awareness of no undisclosed material adverse information. The notice satisfies routine Rule 144 disclosure requirements and does not itself indicate any change in FedEx’s operations or outlook.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.� On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A� code denotes acquisition from equity award; “F� code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (�3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Novanta Inc. (NASDAQ: NOVT) entered into a Fourth Amended & Restated Credit Agreement on 27 June 2025 that replaces its 2019 facility scheduled to mature in March 2027. The new agreement provides an aggregate senior secured credit capacity of approximately US$1.0 billion, broken down into:
- �65.31 million 5-year Euro-denominated term loan
- $75 million 5-year US-dollar term loan
- $850 million 5-year revolving credit facility
The maturity is extended to June 2030, and an uncommitted accordion feature can raise total commitments by an additional $350 million, subject to customary conditions. Interest is set at (i) Base Rate + 0�0.75 ppt or (ii) SOFR/SONIA/EURIBOR + 1.00�1.75 ppt, with pricing tied to the company’s consolidated leverage ratio. A commitment fee applies to unused revolver capacity.
Key financial covenants tested quarterly include: (1) maximum consolidated leverage ratio of 3.5Ă— (step-up to 4.0Ă— for four quarters following qualifying acquisitions >= $50 million) and (2) minimum fixed-charge coverage ratio of 1.25Ă—. The facilities are secured by senior liens on substantially all assets of Novanta and certain subsidiaries and contain customary negative covenants on mergers, asset sales, indebtedness, investments and liens.
Required quarterly principal amortization begins September 2025 for the Euro term loan and September 2026 for the US term loan, with final balloon payments due at maturity. Prepayments from asset sales, casualty events or incremental debt are mandatory, while voluntary prepayments and commitment reductions are permitted without premium.
Outstanding borrowings under the prior facility were $392.4 million as of 28 March 2025. The new structure enhances liquidity headroom, extends tenor, and provides interest-rate optionality, but also secures the debt and maintains leverage limits that investors should monitor.
Enliven Therapeutics, Inc. (ELVN) � Form 4 insider transaction. Chief Financial Officer Benjamin Hohl exercised 3,250 employee stock options at an exercise price of $2.48 per share and immediately sold the same 3,250 shares under a pre-arranged Rule 10b5-1 trading plan dated 26 Jun 2023.
- Option exercise: 3,250 shares converted from options granted 2 Aug 2021 (portion of a 262,120-share grant that vests monthly through Aug 2025).
- Sales: 3,052 shares sold at a volume-weighted average price (VWAP) of $20.8609 and 198 shares at a VWAP of $21.6583; individual trade ranges were $20.58-$21.575 and $21.5811-$21.788, respectively.
- Holdings after transactions: 23,000 shares of common stock held directly and 115,806 options outstanding.
- The exercise-and-sell was executed the same day (27 Jun 2025) and disclosed 1 Jul 2025.
The transaction represents routine liquidity management by the CFO; the net economic exposure (shares plus remaining options) remains substantial.
Form 4 filing � NewMarket Corporation (NEU)
On July 1, 2025, non-employee director Mark M. Gambill received an annual equity grant of 144 shares of NewMarket common stock under the company’s 2023 Incentive Compensation and Stock Plan. The transaction is coded “A� (acquisition) and carries a stated price of $0, indicating a routine, company-awarded stock grant rather than an open-market purchase.
Following this grant, Gambill’s direct beneficial ownership increased to 3,992 shares. The filing reports no derivative security activity and no dispositions. The director remains classified as an insider (director) for Section 16 purposes, and the form was filed individually, not jointly.
Because the grant size is modest relative to NewMarket’s average daily trading volume and market capitalization, the transaction is considered routine and immaterial to the company’s overall float and insider ownership profile. No implications for earnings, guidance, or strategic direction are disclosed.
AdvanSix Inc. (ASIX) � Form 4 insider filing
Director Patrick Williams reported the award of 5,020 restricted stock units (RSUs) on 18 June 2025 under the company’s 2016 Stock Incentive Plan. The RSUs were granted at $0 cost and will vest in full on 18 June 2026. Following the grant, Williams� direct beneficial ownership rose to 33,641 common shares, which includes 76 dividend-equivalent shares credited on unvested awards. No open-market purchases, sales, or derivative security transactions were reported in the filing.
The disclosure reflects routine director equity compensation intended to align incentives with shareholders and does not represent a material change to the company’s capital structure or insider buying/selling trends.
Form 4 overview
On 18 June 2025, AdvanSix Inc. (ASIX) reported that director Sharon S. Spurlin received 5,020 restricted stock units (RSUs) under the company’s 2016 Stock Incentive Plan. Coded “A� for acquisition, the award was issued at no cash cost and is scheduled to vest in full on 18 June 2026.
After the grant, Spurlin’s direct beneficial ownership rose to 74,746 common shares. The total includes 242 dividend-equivalent shares credited on prior unvested RSUs and deferred stock units, which were exempt from reporting under Rule 16a-11.
No derivative securities, open-market purchases, or sales were reported, making this a routine equity-compensation transaction rather than a signal of trading intent.
AdvanSix Inc. (ASIX) filed a Form 4 on 20 June 2025 disclosing that director Daniel F. Sansone received 5,020 restricted stock units (RSUs) on 18 June 2025 under the company’s 2016 Stock Incentive Plan. The grant, recorded at $0 purchase price, will vest in full on 18 June 2026. Following this transaction, Sansone’s total beneficial ownership stands at 36,288 common shares, which includes 106 dividend-equivalent shares accumulated on previously granted units. No derivative securities were reported, and the filing indicates the transaction was not executed under a Rule 10b5-1 trading plan.
AdvanSix Inc. (ASIX) filed a Form 4 disclosing a routine equity-compensation transaction. On 18-Jun-2025, director Donald P. Newman received 5,020 shares of common stock via a restricted stock unit (RSU) grant under the company’s 2016 Stock Incentive Plan. The transaction code was “A� (acquisition) and carried a stated price of $0 because no cash changed hands. All units will vest in full on 18-Jun-2026.
After the award, Mr. Newman’s direct beneficial ownership rose to 11,049 shares, which figure includes six dividend-equivalent shares automatically credited on previously unvested awards. No derivative securities were reported and no shares were sold.
This filing reflects normal director compensation designed to align governance interests with shareholders. The size of the award appears modest relative to AdvanSix’s market capitalization and does not, by itself, signal any shift in the company’s fundamentals or outlook.
Form 4 overview: On 18 June 2025 AdvanSix Inc. (ticker: ASIX) filed a Form 4 disclosing that director Gena C. Lovett received an equity award under the company’s 2016 Stock Incentive Plan.
The filing reports an automatic grant of 5,020 restricted stock units (RSUs) in AdvanSix common stock, recorded at a price of $0 because it is a compensation award rather than an open-market transaction. Per the footnotes, the RSUs will vest in full on 18 June 2026.
After the transaction, Lovett’s direct beneficial ownership stands at 15,162 shares. This total includes 60 dividend-equivalent stock units credited on previously granted RSUs and deferred stock units, which were exempt from reporting under Rule 16a-11.
The event is coded “A� (acquisition) and involves no sales, options, or other derivative securities. The filing does not reference a Rule 10b5-1 trading plan. Because the award represents routine director compensation and the share count is immaterial relative to AdvanSix’s outstanding shares, the disclosure is largely administrative and is unlikely to move the stock or alter the company’s capital structure.
FAQ
What is the current stock price of Advansix (ASIX)?
What is the market cap of Advansix (ASIX)?
What are the core business areas of Advansix?
How does Advansix maintain its operational efficiency?
Where does Advansix primarily operate its manufacturing facilities?
What role does research and development play at Advansix?
How does Advansix differentiate itself from competitors?
What are the key markets served by Advansix?
How does Advansix manage its global supply chain?
What type of products are included in Advansix's portfolio?
